Tanvi Dhere is a Gastroenterology physician affiliated with Emory University. OpenAlex indexes 72 publications with 1,687 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1365 Clifton Rd NE Bldg B
Atlanta, GA 30322
Telephone
404-778-3184Registry record last updated 8 Jun 2018.
Clinical trials
- Early FMT for C.Difficile
Sponsor: Emory University
- A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20241 payment
- UCB, Inc.Program year20241 payment
- Genentech, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
67%Osmotic Laxative36.3%Gavilyte-G100%Part D≥32 patientsProton pump inhibitor30.8%Omeprazole57%Pantoprazole Sodium43%Part D<11 patientsCancer & immunology
33%TNF inhibitor18.7%Humira Pen100%Part D<11 patientsInterleukin-12 Antagonist14.3%Stelara100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Integration of Radiation Oncology Into the Preclinical Curriculum Through Problem-Based Learning
Practical Radiation Oncology
2023 - Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease
The American Journal of Human Genetics
2021 - Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients
Journal of Clinical Microbiology
2021 - Earlier use of fecal transplant administration during hospitalization for Clostridioides difficile infectionmay improve outcome
European Journal of Gastroenterology & Hepatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”